Semaglutide channel chokes on Rs 100cr excess stock as April generic rush fades
India's Rs 2,000cr obesity drug market is digesting a Rs 100cr inventory overhang after May sales cooled. Stockists are sitting on 50-60 days of semaglutide stock and have paused procurement, per AIOCD-Pharmarack data. Eli Lilly's Mounjaro held the top spot at Rs 136cr, while category value grew just 6% m-o-m against 12% unit growth.
What happened
AIOCD · India's semaglutide therapy market faces Rs 100 crore inventory overhang as May sales slowed sharply after April's generic-launch surge. Stockists
Key facts
- Rs 100 crore excess stock
- 50-60 days inventory
- Rs 2,000 crore obesity market
- 6% m-o-m value growth May
- 12% unit growth
- Mounjaro sales Rs 136 crore
- Rs 2.5 lakh crore pharma retail
Why this matters
The Rs 100cr overhang creates a 6-9 month window to acquire distressed semaglutide inventory or distribution slots from over-leveraged stockists before consolidation resets channel economics.